ENSEM Therapeutics: Funding, Investors & Team (Sep 2026)
ENSEM Therapeutics is a pioneering drug discovery and development company that leverages its unique Kinetic EnsembleTM platform to develop innovative small-molecule precision medicines for oncology, with potential expansion into genetic disorders and other disease areas.
ENSEM Therapeutics has raised $77.0M across 2 funding rounds on record, the most recent a Series A of $10.0M announced in Oct 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ENSEM Therapeutics Company Profile and Key Stats
Latest funding round on record: Oct 2023.
ENSEM Therapeutics Funding Rounds
ENSEM Therapeutics raised $67.0M in a Series A announced in Apr 2022.
1.5 years later, a Series A of $10.0M was announced in Oct 2023.
ENSEM Therapeutics Founders and Leadership Team
Contact details for the ENSEM Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →ENSEM Therapeutics Funding Compared to Other Biotechnology Startups
ENSEM Therapeutics' latest round of $10.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ENSEM Therapeutics in Biotechnology and Medford
Companies Similar to ENSEM Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
ENSEM Therapeutics Funding FAQs
What does ENSEM Therapeutics do?
ENSEM Therapeutics is a pioneering drug discovery and development company that leverages its unique Kinetic EnsembleTM platform to develop innovative small-molecule precision medicines for oncology, with potential expansion into genetic disorders and other disease areas.
How much funding has ENSEM Therapeutics raised?
ENSEM Therapeutics has raised $77.0M across 2 rounds on record. The most recent is a Series A of $10.0M announced in Oct 2023.
When did ENSEM Therapeutics last raise funding?
ENSEM Therapeutics' most recent funding round on record is a Series A of $10.0M, announced in Oct 2023.
Who founded ENSEM Therapeutics?
FundedIQ lists Shengfang Jin (Founder) at ENSEM Therapeutics.
Where is ENSEM Therapeutics headquartered?
ENSEM Therapeutics is based in Medford, Massachusetts, United States.
How many employees does ENSEM Therapeutics have?
ENSEM Therapeutics is in the 11-50 employee band.
How does ENSEM Therapeutics' funding compare to other Biotechnology startups?
ENSEM Therapeutics' latest round of $10.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's ENSEM Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ENSEM Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.